CID Holdco, Inc. Faces Nasdaq Delisting Determination; MVLS Below $50M

What Happened

• On August 6, 2026, CID HoldCo, Inc. (DAIC) reported that Nasdaq’s Listing Qualifications staff determined to delist its common stock under Nasdaq Listing Rule 5450(b)(2)(A) because the company’s Market Value of Listed Securities (MVLS) was below the $50 million requirement.
• The company previously received Nasdaq deficiency notices on February 5, 2026 (MVLS below $50M and a sub-$1.00 closing bid price issue) and on February 10, 2026 (failure to maintain minimum market value of publicly held shares (MVPHS) of $15M). Nasdaq had granted compliance cure periods that expired August 4, 2026 (MVLS and minimum bid price) and August 10, 2026 (MVPHS).
• CID regained compliance with the minimum $1.00 bid-price rule (Nasdaq Rule 5550(a)(2)) for at least 12 consecutive business days ending June 22, 2026, and that matter was closed on June 23, 2026. However, the company did not regain MVLS compliance by the August 4 deadline, triggering the Staff Determination.
• The company plans to appeal by requesting a hearing before a Nasdaq Hearings Panel by 4:00 p.m. ET on August 13, 2026 (a $20,000 filing fee applies). Filing the appeal stays any suspension and the filing of Form 25‑NSE with the SEC, so the common stock will remain listed pending the Hearing. CID also issued a press release on August 12, 2026 reporting the Staff Determination.

Key Details

• Staff Determination date: August 6, 2026.
• Nasdaq rule cited: Listing Rule 5450(b)(2)(A) — MVLS minimum $50,000,000.
• Compliance timeline: deficiency notices Feb 5 & Feb 10, 2026; MVLS cure deadline Aug 4, 2026; MVPHS cure deadline Aug 10, 2026.
• Appeal deadline and fee: request Hearing by Aug 13, 2026 at 4:00 p.m. ET; $20,000 hearing fee.
• Stock status: remains listed on Nasdaq while the Company pursues the Hearing.

Why It Matters

• A Nasdaq delisting determination is material because delisting (if upheld) can reduce liquidity, limit investor access, lower trading volume and visibility, and make it harder for the company to raise capital.
• CID has an active, time-limited option to appeal and keep the stock listed while the appeal is pending, but there is no assurance the Hearings Panel will rule in the company’s favor or grant additional time to cure the MVLS deficiency. Investors should monitor the outcome of the Nasdaq hearing request and any further SEC filings or company disclosures.